Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy

Cancer

Volumn 119, Issue 24, 2013, Pages 4231-4241

  Agarwal, Atin ^a   Chang, George J ^b   Hu, Chung Yuan ^b   Taggart, Melissa ^b   Rashid, Asif ^b   Park, In J ^b   You, Y Nancy ^b   Das, Prajnan ^b   Krishnan, Sunil ^b   Crane, Christopher H ^b   Rodriguez Bigas, Miguel ^b   Skibber, John ^b   Ellis, Lee ^b   Eng, Cathy ^b   Kopetz, Scott ^b   Maru, Dipen M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adenocarcinoma; cancer; chemoradiation; complete; near complete; neoadjuvant therapy; pathologic response; preoperative; rectum; recurrence free survival

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECTUM CARCINOMA; RECTUM RESECTION; RECURRENCE FREE SURVIVAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR INVASION;

ADENOCARCINOMA; CANCER; CHEMORADIATION; COMPLETE; NEAR-COMPLETE; NEOADJUVANT THERAPY; PATHOLOGIC RESPONSE; PREOPERATIVE; RECTUM; RECURRENCE-FREE SURVIVAL;

ADENOCARCINOMA; AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 84889888543     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28331     Document Type: Article

References (27)

1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Bosset J-F, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355: 1114-1123.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345: 638-646.
4. Belluco C, De Paoli A, Canzonieri V, et al. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol. 2011; 18: 3686-3693.
5. Maas M, Nelemans PJ, Valentini V, et al. Long term outcome in patients with pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010; 11: 835-844.
6. de Campos-Lobato LF, Stocchi L, da Luz Moreira A, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011; 18: 1590-1598.
7. Yeo SG, Kim DY, Kim TH, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg. 2010; 252: 998-1004.
8. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005; 23: 8688-8696.
9. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002; 236: 75-81.
10. Wheeler JM, Warren BF, Mortensen NJ, et al. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum. 2002; 45: 1051-1056.
11. Huebner M, Wolff BG, Smyrk TC, et al. Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy. World J Surg. 2012; 36: 675-683.
12. Bouzourene H, Bosman FT, Seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002; 94: 1121-1130.
13. Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012; 30: 1770-1776.
14. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103: 1347-1355.
15. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008; 26: 5344-5351.
16. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007; 31: 58-64.
17. Washington K, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Available at: http://www.cap.org/apps/cap.portal. Accessed March 28, 2013.
18. Edge SB, Boyd DR, Comptom CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer Staging Atlas. 7th ed. New York: Springer; 2010: 140-143.
19. Landis JR, Koch GG,. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 159-174.
20. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73: 2680-2686.
21. Ryan R, Gibbons D, Hyland JM, et al. Pathologic response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005; 47: 141-146.
22. Dworak O, Keilholz L, Hoffmann A,. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997; 12: 19-23.
23. Shia J, Guillem JG, Moore HG, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol. 2004; 28: 215-223.
24. Prowell T, Pazdur R,. Pathologic complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012; 366: 2438-2441.
25. Park IJ, You YN, et al. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2013; 56: 135-141.
26. Collette L, Bosset JF, den Dulk M, et al. European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy&quest A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007; 25: 4379-4386.
27. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 28: 4414-4422.